Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

This study has been terminated.
(Sponsor wanted study rewritten)
Sponsor:
Collaborators:
National Cancer Institute (NCI)
GlaxoSmithKline
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT01550185
First received: March 7, 2012
Last updated: April 4, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2014
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)